Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity
详细信息    查看全文
文摘
ss="listitem" id="list_li0005">
ss="label">•

Dasatinib, a Src inhibitor, was feasible as neoadjuvant therapy for bladder cancer.

ss="label">•

Overall, significant Src pathway inhibition was seen in tumor tissue.

ss="label">•

Cell proliferation and apoptosis were unaltered overall.

ss="label">•

Src inhibition appears ineffective in unselected bladder cancer patients.

ss="label">•

The neoadjuvant trial paradigm may complement drug development.

© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号

地址:北京市海淀区学院路29号 邮编:100083

电话:办公室:(+86 10)66554848;文献借阅、咨询服务、科技查新:66554700